Glycobiology Advance Access originally published online on January 3, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glycobiology, 2003, Vol. 13, No. 6 457-470
© 2003 Oxford University Press
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins
2 Unitat de Bioquímica i Biologia Molecular, Departament de Biologia, Universitat de Girona, Campus de Montilivi s/n. 17071, Girona, Spain
3 Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford OX1 3QU, United Kingdom
Received on October 23, 2002; revised on November 29, 2002; accepted on December 12, 2002
Prostate-specific antigen (PSA) is a glycoprotein secreted by prostate epithelial cells. PSA is currently used as a marker of prostate carcinoma because high levels of PSA are indicative of a tumor situation. However, PSA tests still suffer from a lack of specificity to distinguish between benign prostate hyperplasia and prostate cancer. To determine whether PSA glycosylation could provide a means of differentiating between PSA from normal and tumor origins, N-glycan characterization of PSA from seminal fluid and prostate cancer cells (LNCaP cell line) by sequencing analysis and mass spectrometry was carried out. Glycans from normal PSA (that correspond to low and high pI PSA fractions) were sialylated biantennary complex structures, half of them being disialylated in the low pI PSA fraction and mostly monosialylated in the high pI PSA. PSA from LNCaP cells was purified to homogeneity, and its glycan analysis showed a significantly different pattern, especially in the outer ends of the biantennary complex structures. In contrast to normal PSA glycans, which were sialylated, LNCaP PSA oligosaccharides were all neutral and contained a higher fucose content. In 10–15% of the structures fucose was linked 
1-2 to galactose, forming the H2 epitope absent in normal PSA. GalNAc was increased in LNCaP glycans to 65%, whereas in normal PSA it was only present in 25% of the structures. These carbohydrate differences allow a distinction to be made between PSA from normal and tumor origins and suggest a valuable biochemical tool for diagnosis and follow-up purposes.
1 To whom correspondence should be addressed; e-mail: pauline.rudd{at}bioch.ox.ac.uk or rafael.llorens{at}udg.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Tajiri, C. Ohyama, and Y. Wada Oligosaccharide Profiles of the Prostate Specific Antigen in Free and Complexed Forms from the Prostate Cancer Patient Serum and in Seminal Plasma: a Glycopeptide Approach Glycobiology, January 1, 2008; 18(1): 2 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jackson, R. A. Craven, R. C. Hutson, I. Graze, P. Lueth, R. P. Tonge, J. L. Hartley, J. A. Nickson, S. J. Rayner, C. Johnston, et al. Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer Clin. Cancer Res., December 15, 2007; 13(24): 7370 - 7379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kita, Y. Miura, J.-i. Furukawa, M. Nakano, Y. Shinohara, M. Ohno, A. Takimoto, and S.-I. Nishimura Quantitative Glycomics of Human Whole Serum Glycoproteins Based on the Standardized Protocol for Liberating N-Glycans Mol. Cell. Proteomics, August 1, 2007; 6(8): 1437 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Valenzuela, K. E. Pace, P. V. Cabrera, R. White, K. Porvari, H. Kaija, P. Vihko, and L. G. Baum O-Glycosylation Regulates LNCaP Prostate Cancer Cell Susceptibility to Apoptosis Induced by Galectin-1 Cancer Res., July 1, 2007; 67(13): 6155 - 6162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Barrabes, L. Pages-Pons, C. M. Radcliffe, G. Tabares, E. Fort, L. Royle, D. J. Harvey, M. Moenner, R. A. Dwek, P. M. Rudd, et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer Glycobiology, April 1, 2007; 17(4): 388 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Drake, E. E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta, and O. J. Semmes Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1957 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Dube, J. A. Prescher, C. N. Quang, and C. R. Bertozzi Probing mucin-type O-linked glycosylation in living animals PNAS, March 28, 2006; 103(13): 4819 - 4824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tabares, C. M. Radcliffe, S. Barrabes, M. Ramirez, R. N. Aleixandre, W. Hoesel, R. A. Dwek, P. M. Rudd, R. Peracaula, and R. de Llorens Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA Glycobiology, February 1, 2006; 16(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jung, J. Reiche, A. Boehme, C. Stephan, S. A. Loening, D. Schnorr, W. Hoesel, and P. Sinha Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer Clin. Chem., December 1, 2004; 50(12): 2292 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ohyama, M. Hosono, K. Nitta, M. Oh-eda, K. Yoshikawa, T. Habuchi, Y. Arai, and M. Fukuda Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy Glycobiology, August 1, 2004; 14(8): 671 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Lohmann and C.-W. von der Lieth GlycoFragment and GlycoSearchMS: web tools to support the interpretation of mass spectra of complex carbohydrates Nucleic Acids Res., July 1, 2004; 32(suppl_2): W261 - W266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]
|
|